Evaluation of Amyloid Imaging in People with Metabolic Disorder Identified by Brain FDG-PET as Part of a Complete Medical Checkup
Not Applicable
- Conditions
- Alzheimer disease
- Registration Number
- JPRN-UMIN000011612
- Lead Sponsor
- School of medicine, Keio University
- Brief Summary
Amyloid PET negaitve
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
Disagree
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Each 30 subjects who have abnormal metabolism on an FDG-PET scan and positive amyloid PET (stage 2 preclinical AD) and those who have abnormal metabolism on an FDG-PET scan and normal amyloid PET (which may represent non-preclinical AD but suggest other neurological disease) will be monitored for a long term to assess changes in clinical features and cognitive function over time.
- Secondary Outcome Measures
Name Time Method